- Home
- Publications
- Publication Search
- Publication Details
Title
Triple-negative breast cancer: are we making headway at least?
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 4, Issue 4, Pages 195-210
Publisher
SAGE Publications
Online
2012-05-01
DOI
10.1177/1758834012444711
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors
- (2017) J. J. Mahany et al. JOURNAL OF CLINICAL ONCOLOGY
- First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors
- (2017) S. Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
- (2017) S. J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
- (2017) R. A. Dent et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC).
- (2017) K. L. Tedesco et al. JOURNAL OF CLINICAL ONCOLOGY
- Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.
- (2017) K. A. Gelmon et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
- (2017) J. O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition
- (2012) Siker Kimbung et al. CANCER LETTERS
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast Cancer
- (2011) H Joensuu et al. CANCER RESEARCH
- Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer
- (2011) J O'Shaughnessy et al. CANCER RESEARCH
- 801 ORAL High Throughput Molecular Analyses to Select Patients for Targeted Agents
- (2011) M. Arnedos et al. EUROPEAN JOURNAL OF CANCER
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
- (2011) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications of personalized medicine—perspective from a cancer center
- (2011) Thomas Tursz et al. Nature Reviews Clinical Oncology
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Stratification of Triple-Negative Breast Cancers
- (2011) C. M. Perou ONCOLOGIST
- Treatment of HER2-overexpressing breast cancer
- (2010) J. Baselga ANNALS OF ONCOLOGY
- Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
- (2010) Jens Huober et al. BREAST CANCER RESEARCH AND TREATMENT
- Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
- (2010) Edith A. Perez et al. BREAST CANCER RESEARCH AND TREATMENT
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).
- (2010) W. Gradishar et al. CANCER RESEARCH
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.
- (2010) A. Brufsky et al. CANCER RESEARCH
- SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).
- (2010) J. Baselga et al. CANCER RESEARCH
- Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC).
- (2010) C. Barrios et al. CANCER RESEARCH
- Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).
- (2010) J. O'Shaughnessy et al. CANCER RESEARCH
- Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer
- (2010) S. Y. Park et al. CLINICAL CANCER RESEARCH
- Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study
- (2010) Qing Zeng et al. EUROPEAN JOURNAL OF CANCER
- Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations
- (2010) Gunda Pristauz et al. HISTOPATHOLOGY
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas)
- (2010) C. Marchio et al. JOURNAL OF CLINICAL PATHOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
- (2010) Felipe C Geyer et al. MODERN PATHOLOGY
- Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer
- (2010) Miguel Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers
- (2010) J. Lehmann-Che et al. ONCOLOGIST
- Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer
- (2009) B. K. Linderholm et al. ANNALS OF ONCOLOGY
- mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
- (2009) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair
- (2009) E. Bolderson et al. CLINICAL CANCER RESEARCH
- Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array
- (2009) F. Andre et al. CLINICAL CANCER RESEARCH
- Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
- (2009) Judith Hugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
- (2009) Leo A Niemeier et al. MODERN PATHOLOGY
- Platinum-based chemotherapy in triple-negative breast cancer
- (2008) B. Sirohi et al. ANNALS OF ONCOLOGY
- Pattern of metastatic spread in triple-negative breast cancer
- (2008) Rebecca Dent et al. BREAST CANCER RESEARCH AND TREATMENT
- Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity
- (2008) Giuseppe Viale et al. BREAST CANCER RESEARCH AND TREATMENT
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer
- (2008) Nancy U. Lin et al. CANCER
- Therapeutic Strategies for Triple-Negative Breast Cancer
- (2008) Antoinette R. Tan et al. CANCER JOURNAL
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
- (2008) M. C.U. Cheang et al. CLINICAL CANCER RESEARCH
- DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy
- (2008) S. Ashwell et al. CLINICAL CANCER RESEARCH
- Keeping checkpoint kinases in line: new selective inhibitors in clinical trials
- (2008) Susan Ashwell et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype
- (2008) David Voduc et al. HUMAN PATHOLOGY
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum
- (2008) Marick Laé et al. MODERN PATHOLOGY
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
- Triple-negative/basal-like breast cancer: review
- (2008) Emad A. Rakha et al. PATHOLOGY
- HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
- (2007) Alessandra Gennari et al. JNCI-Journal of the National Cancer Institute
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now